PMID- 32801618
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1177-5467 (Print)
IS  - 1177-5483 (Electronic)
IS  - 1177-5467 (Linking)
VI  - 14
DP  - 2020
TI  - Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients 
      Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN((R))) and Follow-Up 
      Considerations/Recommendations.
PG  - 2091-2107
LID - 10.2147/OPTH.S252359 [doi]
AB  - Current management of diabetic macular edema (DME) predominantly involves 
      treatment with short-acting intravitreal injections of anti-vascular endothelial 
      growth factors (anti-VEGFs) and/or corticosteroids; however, short-acting 
      therapies (lasting between 1 and 6 months) require frequent injections to 
      maintain efficacy, meaning a considerable treatment burden for diabetic patients 
      with multiple comorbidities. Continuous injections needed in some cases are an 
      economic burden for patients/healthcare system, so real-life clinical practice 
      tends to adopt a reactive approach, ie, watch and wait for worsening symptoms, 
      which consequently increases the risk of undertreatment and edema recurrence. On 
      March 7th 2019, a group of experts in retinal medicine and surgery held a 
      roundtable meeting in Madrid, Spain to discuss how to (1) optimize clinical 
      outcomes through earlier use of fluocinolone acetonide (FAc) implant (ILUVIEN((R))) 
      in patients with persistent or recurrent DME despite therapy; and, (2) to provide 
      guidance to assist physicians in deciding which patients should be treated with 
      ILUVIEN. In this regard, a 36-month follow-up consensus protocol is presented. In 
      conclusion, patients that achieve a complete or partial anatomical, and 
      preferably functional, response following one or two intravitreal dexamethasone 
      implants, but with recurrence of edema after 3-4 months, are deemed by the 
      authors most likely to benefit from ILUVIEN, and the switch to FAc implant should 
      not be delayed more than 12 months after the initiation of at least the first 
      dexamethasone implant.
CI  - (c) 2020 Adan et al.
FAU - Adan, Alfredo
AU  - Adan A
AUID- ORCID: 0000-0001-8923-2200
AD  - Hospital Clinic de Barcelona, Barcelona, Spain.
FAU - Cabrera, Francisco
AU  - Cabrera F
AUID- ORCID: 0000-0002-5074-5102
AD  - Complejo Hospitalario Universitario Insular Materno-Lnfantil de Gran Canaria, Las 
      Palmas de Gran Canaria, Spain.
FAU - Figueroa, Marta S
AU  - Figueroa MS
AD  - Hospital Universitario Ramon y Cajal, Madrid, Spain.
FAU - Cervera, Enrique
AU  - Cervera E
AD  - Hospital General Universitario de Valencia, Valencia, Spain.
FAU - Ascaso, Francisco J
AU  - Ascaso FJ
AD  - Hospital Clinico Universitario Lozano Blesa de Zaragoza, Aragon Health Research 
      Institute (IIS Aragon), Zaragoza, Spain.
FAU - Udaondo, Patricia
AU  - Udaondo P
AUID- ORCID: 0000-0002-5241-0066
AD  - Hospital Universitario y Politecnico la Fe de Valencia, Valencia, Spain.
FAU - Abraldes, Maximino
AU  - Abraldes M
AUID- ORCID: 0000-0001-8100-5433
AD  - Complexo Hospitalario Universitario de Santiago de Compostela, Universidad de 
      Santiago de Compostela, Instituto Oftalmologico Gomez-Ulla, Santiago de 
      Compostela, Spain.
FAU - Reyes, Miguel Angel
AU  - Reyes MA
AUID- ORCID: 0000-0001-7128-8134
AD  - Hospital Universitario de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, 
      Spain.
FAU - Pazos, Marta
AU  - Pazos M
AD  - Hospital Clinic de Barcelona, Barcelona, Spain.
FAU - Pessoa, Bernardete
AU  - Pessoa B
AUID- ORCID: 0000-0002-5673-1561
AD  - Centro Hospitalar e Universitario do Porto, Hospital Geral de Santo Antonio, 
      Porto, Portugal.
FAU - Armada, Felix
AU  - Armada F
AUID- ORCID: 0000-0002-3695-3343
AD  - Hospital Universitario La Paz, Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200724
PL  - New Zealand
TA  - Clin Ophthalmol
JT  - Clinical ophthalmology (Auckland, N.Z.)
JID - 101321512
PMC - PMC7398681
OTO - NOTNLM
OT  - DME
OT  - ILUVIEN
OT  - diabetic macular edema
OT  - fluocinolone acetonide implant therapy
COIS- Alfredo Adan declares financial support from Allergan, Bayer, Brill Pharma, 
      Alimera and Novartis; Francisco Cabrera and Marta S. Figueroa declare financial 
      support from Alcon, Allergan, Bayer, Brill Pharma, Novartis, and Roche; Patricia 
      Udaondo declares financial support from Alimera, Allergan, Bayer, Bausch and 
      Lomb, Brill Pharma, Graybug, Novartis, Roche; Maximino Abraldes declares 
      financial support from Allergan, Bayer, Brill Pharma, Boehringer Ingelheim, 
      Novartis, Ophthotech and Roche; Miguel Angel Reyes declares financial support 
      from Alcon, Bayer, Novartis and Brill Pharma; Marta Pazos declares financial 
      support from Allergan, Santen, Brill Pharma, VISUfarma, and Zeiss, including 
      non-financial support from Heidelberg Engineering; and Felix Armada declares 
      financial support from Bayer, Novartis, Alcon, Medical Mix, Zeiss, Allergan, 
      Bausch & Lomb and Dorc. The authors report no other conflicts of interest in this 
      work.
EDAT- 2020/08/18 06:00
MHDA- 2020/08/18 06:01
PMCR- 2020/07/24
CRDT- 2020/08/18 06:00
PHST- 2020/03/03 00:00 [received]
PHST- 2020/06/21 00:00 [accepted]
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2020/08/18 06:01 [medline]
PHST- 2020/07/24 00:00 [pmc-release]
AID - 252359 [pii]
AID - 10.2147/OPTH.S252359 [doi]
PST - epublish
SO  - Clin Ophthalmol. 2020 Jul 24;14:2091-2107. doi: 10.2147/OPTH.S252359. eCollection 
      2020.